Direct-to-consumer prescription drug advertising in Canada: permission by default?

The advertising of prescription drugs aimed directly at the public is prohibited in most countries, including Canada. However, a shift in interpretation of the policy governing this marketing strategy, known as direct-to-consumer advertising (DTCA), has occurred in Canada, resulting in its partial

[1]  Jeffrey B. Gross,et al.  Timing of New Black Box Warnings and Withdrawals for Prescription Medications , 2003 .

[2]  T. Bodenheimer.  Two advertisements for TV drug ads. , 2003, Health affairs.

[3]  D. Blumenthal,et al.  Consumers' reports on the health effects of direct-to-consumer drug advertising. , 2003, Health affairs.

[4]  J. Lexchin,et al.  Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No , 2002 .

[5]  J. Calfee.  Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs , 2002 .

[6]  A. Holmer.  Direct-to-consumer advertising--strengthening our health care system. , 2002, The New England journal of medicine.

[7]  R. Kravitz,et al.  Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey , 2002, BMJ : British Medical Journal.

[8]  J. Lexchin.  Should doctors be prescribing new drugs , 2002 .

[9]  Alan Lyles,et al.  Direct marketing of pharmaceuticals to consumers. , 2002, Annual review of public health.

[10]  Lisa M. Schwartz,et al.  Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? , 2001, The Lancet.

[11]  A. Silversides.  Direct-to-consumer prescription drug ads getting bolder. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  E. Gale.  Lessons from the glitazones: a story of drug development , 2001, The Lancet.

[13]  R. Kravitz,et al.  The educational value of consumer-targeted prescription drug print advertising. , 2000, The Journal of family practice.

[14]  T. Bodenheimer.  Making Medicine, Making Money , 1993 .

[15]  D. Raiford,et al.  Therapeutic Ratings and End‐of‐Phase II Conferences: Initiatives to Accelerate the Availability of Important New Drugs Kenneth I. Kaitin, PhD , 1991, Journal of clinical pharmacology.